Better Late Than Never? Maybe.

Hot on the heels of the successful launch of Incivek, Vertex Pharmaceuticals (Nasdaq: VRTX  ) is going after another large market. Unlike hepatitis C, though, the biotech isn't the front runner for rheumatoid arthritis. Not even close.

The data released today from a phase 2a trial looked pretty good. There was a nice dose response for VX-509, which is a good sign that the results are due to the drug and not just random. At the top two doses, VX-509 showed statistically significant improvement across four different measurements of rheumatoid arthritis symptoms.

But there are plenty of oral rheumatoid arthritis drugs headed quickly toward the market already. Pfizer's (NYSE: PFE  ) tofacitinib has already posted phase 3 trial results and it'll likely be on the market next year. Incyte (Nasdaq: INCY  ) and Eli Lilly's (NYSE: LLY  ) LY3009104 and Rigel Pharmaceuticals (Nasdaq: RIGL  ) and AstraZeneca's (NYSE: AZN  ) fostamatinib are both ahead of VX-509.

While the data for VX-509 looks good, it's nearly impossible to compare it to the clinical trials run by Vertex's competitors. Pain is one of the major symptoms of rheumatoid arthritis and is quite subjective, resulting in placebo effects that can vary considerably. In one of Pfizer's trials, for instance, 26.7% of patients receiving placebo reported a 20% improvement in their symptoms, while in another trial, 31.2% of placebo patients reported the same improvement.

The market for rheumatoid arthritis drugs is certainly big enough for three or four players. It's currently dominated by three multi-billion-dollar drugs, but they have to be injected or infused, so they're ripe to be picked off by the oral drugs.

Vertex's investors will just have to take a wait-and-see attitude here. The company plans to run a phase 2b trial, which will test the drug for twice as long as the most recent trial. And then it'll need a couple of phase 3 trials to get on the market. Being late to the game, Vertex needs to hope that its competitors slip up or that the efficacy and/or safety data for VX-509 differentiates it from the leaders.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1549052, ~/Articles/ArticleHandler.aspx, 11/28/2014 9:52:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement